w/in 30 min following of esmolol infusion Henthorn 34 Flecainide Placebo PSVT Syncope, angina, or Freedom from Significantly Flecainide N/A Despite 1991 for (n=34) (n=34) transient cerebral symptomatic more side vs. placebo: participation (26) 8-wk events during PSVT, PSVT at 60 d: effects w/ of 19 medical of second or third 79% events flecainide Recurrence: centers, only (after degree AV block or vs. 15% (p<0.05) 8/34 vs. 34 pts four had CHF (NYHA (p<0.001) 29/34 completed PSVT (p<0.001). entire protocol (≥2 of PSVT Flecainide and provided episodes or end of slowed Median time analyzable ) symptomatic to first event: data. period) PSVT HR to 55 vs. 11 143±12 bpm (p<0.001) All pts from 178 ±12 tolerated on placebo in Median flecainide, 7 pts who had interval limiting events in the between placebo and episodes flecainide >55 vs. 12 d treatment (p<0.001) phases monitoring (p<0.02) does not permit assessment of proarrhythmia . 6/34 w/ AVNRT, confirmed by EP study, and 18/34 w/ unknown mechanism. Pritchett 42 Flecainide Placebo PSVT, PAF, or Syncope, angina, or Among 14 pts Noncardiac N/A N/A Small sample given in inserted at paroxysmal atrial transient cerebral in Group 1 adverse size, short (27) ascending random flutter events during PSVT, (PSVT) who experiences treatment efficacy order (alternating w/ second or third qualified for were leading period. of (2550100150 flecainide) at degree AV block or efficacy cause of mg bid) 30 d intervals had CHF (NYHA analysis, 4 premature in (29%) had no study patents PSVT tachycardia discontinuation w/ (n=14, Group while taking during
w/in 30 min following of esmolol infusion Henthorn 1991 (26) for of PSVT (≥2 34 8-wk (after four episodes of PSVT or end of period) Flecainide (n=34) Placebo (n=34) PSVT Syncope, angina, or transient cerebral events during PSVT, second or third degree AV block or had CHF (NYHA Freedom from symptomatic PSVT at 60 d: 79% events vs. 15% (p<0.001) Flecainide slowed symptomatic PSVT HR to 143±12 bpm from 178 ±12 on placebo in 7 pts who had events in the placebo and flecainide treatment phases (p<0.02) Significantly more side effects w/ flecainide (p<0.05) Flecainide vs. placebo: Recurrence: 8/34 vs. 29/34 (p<0.001). Median time to first event: 55 vs. 11 (p<0.001) Median interval between episodes >55 vs. 12 d (p<0.001) N/A Despite participation of 19 medical centers, only 34 pts completed entire protocol and provided analyzable data. All pts tolerated flecainide, limiting monitoring does not permit assessment of 6/34 w/ AVNRT, confirmed by EP study, and 18/34 w/ unknown mechanism. (27) efficacy of in patents w/ 42 Flecainide given in ascending order (2550100150 mg bid) PSVT (n=14, Group Placebo inserted at random (alternating w/ flecainide) at 30 d intervals PSVT, PAF, or paroxysmal atrial flutter Syncope, angina, or transient cerebral events during PSVT, second or third degree AV block or had CHF (NYHA . Among 14 pts in Group 1 (PSVT) who qualified for efficacy analysis, 4 (29%) had no tachycardia while taking Noncardiac adverse experiences were leading cause of premature study discontinuation during N/A N/A Small sample size, short treatment period. Pritchett proarrhythmia )
2015_SVT_Evidence_Tables_Data_Supplement.docx